919286-58-1

Usage

Uses

Used in Pharmaceutical Industry:
(R)-4-Boc-broMoMethylMorpholine is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure and Boc protection allow for selective reactions, facilitating the creation of complex molecules with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical field, (R)-4-Boc-broMoMethylMorpholine serves as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its ability to be selectively modified and incorporated into larger molecules makes it a valuable intermediate for developing effective and targeted agrochemical products.
Used in Medicinal Chemistry:
(R)-4-Boc-broMoMethylMorpholine is utilized as an intermediate in the preparation of chiral amines, which are essential in the synthesis of enantiomerically pure compounds. These compounds are crucial for the development of drugs with specific biological activities, as the stereochemistry of a molecule can greatly influence its pharmacological properties.
Used in Drug Discovery:
(R)-4-Boc-broMoMethylMorpholine plays a significant role in drug discovery, where its unique structure and Boc protection enable the exploration of novel chemical spaces and the development of potential drug candidates. The selective reactivity provided by the Boc group allows for the synthesis of diverse and complex molecules with potential therapeutic applications.

Upstream product

• 884512-77-0 (R)-4-(tert-butyloxycarbonyl)morpholine-2-carboxylic acid 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 

Downstream Products

• 879403-42-6 tert-butyl (2S)-2-(aminomethyl)morpholine-4-carboxylate 

Relevant academic research and scientific papers

P2X3 MODULATORS

Provided herein are P2X3 modulators and methods of utilizing P2X3 modulators in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Ni-Catalyzed Formal Cross-Electrophile Coupling of Alcohols with Aryl Halides

Direct coupling of unactivated alcohols remains a challenge in current synthetic chemistry. We herein demonstrate a strategy building upon in situ halogenation/reductive coupling of alcohols with aryl halides to forge Csp2-Csp3 bonds. The combination of 2-chloro-3-ethylbenzo[d]oxazol-3-ium salt (CEBO) and TBAB as the mild bromination reagents enables rapid transformation of a wide range of alcohols to their bromide counterparts within one to 5 min in CH3CN and DMF, which is compatible with the Ni-catalyzed cross-electrophile coupling conditions in the presence of a chemical reductant. The present method is suitable for arylation of a myriad of structurally complex alcohols with no need for prepreparation of alkyl halides. More importantly, the mild and kinetically rapid bromination process has shown good selectivity in the bromination/arylation of symmetric diols and less sterically hindered hydroxyl groups in polyols, thus offering promise for selective functionalization of diols and polyols without laborious protecting/deprotecting operations. The practicality of this work is also evident in the arylation of a number of carbohydrates, drug compounds, and naturally occurring alcohols.

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.

CYSTEINE PROTEASE INHIBITORS

Stereoisomers of the formula (III) wherein R is H or C1-C3 optionally halo-substituted alkyl; or pharmaceutically acceptable salts, hydrates or N-oxides thereof have utility in the treatment of disorders mediated by inappropriate exp